Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio Inc (ANVS) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. This page aggregates all material announcements, regulatory filings, and research developments related to their drug pipeline.
Investors and researchers will find timely updates on clinical trial progress for lead candidate buntanetap, intellectual property milestones, and strategic collaborations. The curated news collection provides essential context for evaluating the company's scientific approach to targeting multiple neurotoxic proteins.
Key content includes updates on Phase III trial outcomes, FDA communications, partnership agreements with academic institutions, and financial reporting. All information is sourced from verified channels to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined tracking of ANVS's progress in developing therapies that address both chronic neurodegeneration and acute neural injury. Regular updates provide critical insights for stakeholders monitoring advancements in dementia treatment research.
On September 1, 2020, Annovis Bio Inc. (ANVS) announced the dosing of the first three patients in its Phase 2a clinical trial for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The trial, which has IRB approval, will enroll a total of 28 patients over four weeks, focusing on the drug ANVS401's ability to reverse toxic nerve cell death. Initial data is expected in early 2021, followed by a larger dose-response trial. This is a significant milestone for the company, which aims to offer a novel treatment for these neurodegenerative diseases.
Annovis Bio Inc. (NYSE American:ANVS) announced its participation in the LD 500 investor conference on September 1, 2020, at 9:20 AM EDT. CEO Maria Maccecchini will present the company’s innovative approach to treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The company is currently conducting two Phase 2 trials focused on these conditions. The LD 500, running from September 1-4, will be virtual, making it accessible to all interested parties. For more information, visit annovisbio.com.
Annovis Bio Inc. (NYSE American: ANVS) has resumed patient recruitment for its suspended Phase 2a clinical trial targeting Alzheimer’s disease (AD) and initiated a new Phase 2a trial for both AD and Parkinson’s disease (PD). The first trial involves 24 patients and is in collaboration with major institutions. Initial data is expected in early 2021. The second trial will also enroll patients across 15 US sites, with results anticipated in summer 2021. The company plans to report final data from long-term toxicology studies by fall 2020 to confirm the safety of its lead compound, ANVS401.
On July 23, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini will appear on Executive Leaders Radio on July 26, 2020. The show focuses on interviews with prominent CEOs, particularly within life sciences, discussing professional success and personal stories. Dr. Maccecchini expressed her enthusiasm for sharing the Annovis story and her personal commitment to neurodegeneration solutions. Annovis Bio, based in Berwyn, PA, is focused on developing drugs for Alzheimer’s and Parkinson’s diseases, with ongoing Phase 2a studies targeting these conditions.
Annovis Bio (NYSE American: ANVS) announces that CEO Maria Maccecchini, Ph.D., will present at the University of Pennsylvania on July 20, 2020. Her talk, titled “Rethinking Parkinson’s Disease”, addresses a novel treatment approach for Parkinson's disease at the Parkinson’s Disease and Movement Disorders Center, recognized as a global Center of Excellence.
Maccecchini will discuss the toxic cascade caused by neurotoxic proteins in neurodegenerative diseases, presenting data from clinical trials using ANVS401, Annovis Bio's lead compound.
Annovis Bio (ANVS) has received Central IRB approval to initiate a Phase 2 clinical study targeting early Parkinson's disease (PD) and Alzheimer's disease (AD) patients. The study will involve 68 patients over four weeks, assessing the lead compound, ANVS401, for its effects on nerve cell death and cognitive functions. The trial aims to understand safety, tolerability, and the potential reversal of toxic cascades affecting nerve cells. CEO Maria Maccecchini expressed optimism about staying on schedule to complete the study by Q1 2021, despite initial delays related to COVID-19.
Annovis Bio Inc. (NYSE American: ANVS) announced the successful completion of a chronic toxicology study for its lead compound, ANVS401, with no adverse side effects reported in rats. Funded by a $1.7 million NIH grant, this six-month study corroborates previous positive results from shorter studies. CEO Maria Maccecchini highlighted this milestone as critical for advancing long-term human studies. Ongoing safety studies on dogs are anticipated to yield results in Q3 2020, supporting Annovis's ongoing clinical trials for Alzheimer's and Parkinson's diseases.
On June 9, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, Ph.D., and CFO, Jeff McGroarty, MBA, CPA, will present virtually at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020. The presentation is scheduled for June 10 at 10:55 a.m. ET, followed by a live Q&A session. Annovis Bio focuses on developing treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies to improve neurodegeneration. Investors can register for the summit and access the live webcast online.
On June 2, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that the European Patent Office granted a patent for a method to treat Alzheimer's disease with its lead compound, ANVS401. This patent complements the existing US patent for Parkinson's Disease. CEO Maria Maccecchini highlighted plans for additional patents targeting various neurodegenerative diseases. Annovis Bio is conducting two Phase 2 studies of ANVS401 to demonstrate its efficacy in preserving nerve cell function in Alzheimer's and Parkinson's patients.
Annovis Bio (NYSE American: ANVS) announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 10:00 a.m. ET. Shareholders are encouraged to attend and vote using their Virtual Control Number. The Notice of Annual Meeting, Proxy Statement, and Annual Report for the year ended December 31, 2019, are accessible online. The company is focused on developing treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, with ongoing clinical trials aimed at improving patient outcomes.
FAQ
What is the current stock price of Annovis Bio (ANVS)?
What is the market cap of Annovis Bio (ANVS)?
